Abstract:
A system and a methodology to improve the end-user quality of service both in terms of response time and reliability for the transport of in-call DTMF signals in wireless systems, particularly in geostationary mobile satellite systems. The methodology encompasses several techniques to provide acceptable end-to-end quality of service for DTMF. A technique is applicable for transport of DTMF in the wireless subscriber to network direction, where DTMF digits are carried in the form of an out-band message. The central part of the technique is to allow multiple key presses in the same message, thereby increasing efficiency and throughput in long-delay environment. Another technique utilizes the vocoder's functionality to carry DTMF in-band, thereby reducing system complexity. The scheme makes the use of an integrated DTMF detector which can classify a given frame of signal into several classes so that the DTMF encoded packet can carry a unique pattern across the air-interface to the voice decoder at AT, which is capable of identifying the pattern. Another technique pertains to the use of a message based DTMF transport between two-ATs on a separate logical channel with a unique Service Access point Identifier (SAPI) providing guaranteed service for DTMF transport in an AT-AT call.
Abstract:
Disclosed are novel 4-alkenyl- and 4-alkynyl oxindoles having the formula and the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, a, b, and X are as defined herein. These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer, more particularly, the treatment or control of breast and colon tumors. Also disclosed are pharmaceutical compositions containing the compounds of formula I and II as well as intermediates useful in the preparation of the compounds of formula I and II.
Abstract:
Disclosed are novel 4-alkenyl- and 4-alkynyl oxindoles having the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, a, b, and X are as defined herein. These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer, more particularly, the treatment or control of breast and colon tumors. Also disclosed are pharmaceutical compositions containing the compounds of formula I and II as well as intermediates useful in the preparation of the compounds of formula I and II.
Abstract:
FIG. 1 is a front elevation view of a smartwatch case showing the new design; FIG. 2 is a back elevation view thereof; FIG. 3 is a left-side view thereof; FIG. 4 is a right-side view thereof; FIG. 5 is a top plan view thereof; FIG. 6 is a bottom plan view thereof; FIG. 7 is a perspective view thereof; and, FIG. 8 is another perspective view thereof. The broken lines depict portions of the smartwatch case and form no part of the claimed design.
Abstract:
A method of forming an array of nanostructures includes forming a plurality of seed points on a surface of a substrate, and growing masks from the seed points to create masked regions of the substrate underlying the masks. A remainder of the substrate comprises an unmasked region. Each mask and masked region increase in size with growth time while the unmasked region of the substrate decreases in size. During the growing, the unmasked region is etched to remove material from the substrate in a depth direction, and, simultaneously, unetched structures are formed from the masked regions of the substrate underlying the masks. Each of the unetched structures has a lateral size that increases with depth.
Abstract:
Provided are a camptothecin compound containing 7-membered lactone ring, as shown in general formula I, and pharmaceutically acceptable salt thereof, as well as the preparation method and use thereof. In general formula I, R1 is H, a C1˜C3 alkyl, acetyl or propionyl; R2 is H, a C1˜C6 alkyl, a C3˜C6 cycloalkyl, piperidyl; or a C1˜C6 alkyl substituted by an amino; R3 is H, a C1˜C3 alkyl, or a C1˜C6 alkyl substituted by an amino; R4 is H, a hydroxyl, or a C1˜C6 alkoxy; R5 is H, or a C1˜C6 alkoxyl; or R4 and R5 are linked to each other to form —OCH2O— or —OCH2CH2O—. The compound has good anti-tumor activity, and can be clinically used via oral administration, intravenous injection, and intramuscular injection, among others.
Abstract:
The present invention is directed to pharmaceutical compositions comprising: (a) a cyclopolysaccharide and (b) a compound of Formula (I) or its pharmaceutical acceptable salt: wherein X1, X2, Q, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compositions.
Abstract:
The disclosure includes hydroxamic compounds of Formula I: (Formula I) wherein Z, L, R1, R2, and R3 are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.